Koó E - Search Results

1

Measurement of disease activity in psoriatic arthritis. Extended report.

Ujfalussy I, Koó E. Ujfalussy I, et al. Among authors: koo e. Z Rheumatol. 2003 Feb;62(1):60-5. doi: 10.1007/s00393-003-0455-5. Z Rheumatol. 2003. PMID: 12624805

2

Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.

Ujfalussy I, Koó E, Seszták M, Gergely P. Ujfalussy I, et al. Among authors: koo e. Z Rheumatol. 2003 Apr;62(2):155-60. doi: 10.1007/s00393-003-0458-2. Z Rheumatol. 2003. PMID: 12721703

3

Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey.

Brodszky V, Péntek M, Bálint PV, Géher P, Hajdu O, Hodinka L, Horváth G, Koó E, Polgár A, Seszták M, Szántó S, Ujfalussy I, Gulácsi L. Brodszky V, et al. Among authors: koo e. Scand J Rheumatol. 2010 Aug;39(4):303-9. doi: 10.3109/03009740903468982. Scand J Rheumatol. 2010. PMID: 20166848

4

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.

Brodszky V, Bálint P, Géher P, Hodinka L, Horváth G, Koó É, Péntek M, Polgár A, Seszták M, Szántó S, Ujfalussy I, Gulácsi L. Brodszky V, et al. Among authors: koo e. Rheumatol Int. 2009 Dec;30(2):199-205. doi: 10.1007/s00296-009-0936-1. Rheumatol Int. 2009. PMID: 19381635

5

Termination of disease modifying antirheumatic drugs in psoriatic arthritis.

Ujfalussy I, Koó E, Seszták M. Ujfalussy I, et al. Among authors: koo e. J Rheumatol. 2001 Mar;28(3):682-3. J Rheumatol. 2001. PMID: 11296986 Clinical Trial. No abstract available.

6

Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases.

Polgár A, Falus A, Koó E, Ujfalussy I, Seszták M, Szuts I, Konrád K, Hodinka L, Bene E, Mészáros G, Ortutay Z, Farkas E, Paksy A, Buzás EI. Polgár A, et al. Among authors: koo e. Rheumatology (Oxford). 2003 Apr;42(4):522-7. doi: 10.1093/rheumatology/keg168. Rheumatology (Oxford). 2003. PMID: 12649398

7

[The role of biological agents in the treatment of psoriatic arthritis, literature review].

Koó E, Brodszky V, Péntek M, Ujfalussy I, Nagy MB, Gulácsi L. Koó E, et al. Orv Hetil. 2006 Oct 15;147(41):1963-70. Orv Hetil. 2006. PMID: 17120686 Review. Hungarian.

8

Systemic, secondary amyloidosis in a patient with psoriatic arthritis.

Ujfalussy I, Bély M, Koó E, Seszták M. Ujfalussy I, et al. Among authors: koo e. Clin Exp Rheumatol. 2001 Mar-Apr;19(2):225. Clin Exp Rheumatol. 2001. PMID: 11326492 No abstract available.

9

[Drugs that induce and/or worsen psoriasis].

Koó E, Seszták M, Gyulai F, Ujfalussy I. Koó E, et al. Orv Hetil. 1988 Aug 7;129(32):1699-701. Orv Hetil. 1988. PMID: 2902548 Review. Hungarian. No abstract available.

10

Juvenile psoriatic arthritis.

Koó E, Balogh Z, Gömör B. Koó E, et al. Clin Rheumatol. 1991 Sep;10(3):245-9. doi: 10.1007/BF02208685. Clin Rheumatol. 1991. PMID: 1790632

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

468 results

Search Page

Filters